You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

CLINICAL TRIALS PROFILE FOR SILODOSIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Silodosin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00224107 ↗ A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo Completed Watson Pharmaceuticals Phase 3 2005-05-01 A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
NCT00224120 ↗ A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo Completed Watson Pharmaceuticals Phase 3 2005-05-01 A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
NCT00224133 ↗ The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Completed Watson Pharmaceuticals Phase 3 2005-09-01 A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Silodosin

Condition Name

Condition Name for Silodosin
Intervention Trials
Benign Prostatic Hyperplasia 7
Kidney Stones 2
Lower Ureteric Stones 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Silodosin
Intervention Trials
Prostatic Hyperplasia 12
Hyperplasia 11
Ureterolithiasis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Silodosin

Trials by Country

Trials by Country for Silodosin
Location Trials
United States 130
Korea, Republic of 9
China 4
Japan 2
Taiwan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Silodosin
Location Trials
Pennsylvania 7
California 6
New York 6
Florida 5
Alabama 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Silodosin

Clinical Trial Phase

Clinical Trial Phase for Silodosin
Clinical Trial Phase Trials
Phase 4 9
Phase 3 9
Phase 2 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Silodosin
Clinical Trial Phase Trials
Completed 17
Not yet recruiting 4
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Silodosin

Sponsor Name

Sponsor Name for Silodosin
Sponsor Trials
Watson Pharmaceuticals 6
JW Pharmaceutical 5
Benha University 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Silodosin
Sponsor Trials
Other 24
Industry 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.